Skip to content
drillr.ai
Sign up

600422.SH

昆药集团

SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

CNY 8.31
−2.69%
Ask drillr

  • Sep 1, 2026, 09:09 UTC

    Kunming Pharma Group received regulatory acceptance to register medium-term notes of up to 1 billion yuan, valid for two years, with phased issuance allowed.

    Source:

  • Aug 21, 2026, 11:05 UTC

    Kunming Pharma Group reported first-half 2026 revenue of 1.643 billion yuan, down 50.97% year-on-year, and a net loss attributable to shareholders of 364 million yuan, down 283.48% year-on-year.

    Source:

  • Aug 21, 2026, 11:04 UTC

    Kunming Pharma Group announced plans to conduct accounts receivable factoring business with China Resources Commercial Factoring, with total financing not exceeding 200 million yuan.

    Source:

  • Aug 12, 2026, 07:23 UTC

    Hangzhou Bailun Testing Technology, a wholly-owned subsidiary of Baicheng Pharmaceutical, won a procurement contract from Kunming Pharmaceutical Group for gene toxicity impurity assessment services.

    Source:

  • Jul 24, 2026, 09:42 UTC

    Kunming Pharmaceutical Group plans to sell up to 244.3022 million shares of Viva Biotech (09887.HK) after the lock-up period expires on July 25, 2026, with an estimated transaction amount of 132 million yuan.

    Source: